Thiazolidinediones reduce risk of NAFLD
Thiazolidinediones (TZDs) are beneficial for certain selected patients at risk of Non-Alcoholic Fatty Liver Disease (NAFLD), according to a study published in the Hepatology.Thiazolidinediones (TZDs) and glucagon-like peptide-1 (GLP-1) receptor agonists are potential pharmacological treatment options for patients at risk of Non-Alcoholic Fatty Liver Disease (NAFLD). Therefore, a group...
Thiazolidinediones (TZDs) are beneficial for certain selected patients at risk of Non-Alcoholic Fatty Liver Disease (NAFLD), according to a study published in the Hepatology.
Thiazolidinediones (TZDs) and glucagon-like peptide-1 (GLP-1) receptor agonists are potential pharmacological treatment options for patients at risk of Non-Alcoholic Fatty Liver Disease (NAFLD). Therefore, a group of researchers examined the association between the risk of NAFLD and the use of TZDs and GLP-1 receptor agonists compared with the use of sulfonylureas (SUs) and insulins. Additionally, the researchers calculated the incidence of HCC in users of TZDs and GLP-1 receptor agonists.
For more details, check out the full story on the link below:
Thiazolidinediones May Significantly Reduce Risk Of NAFLD, Finds Study
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd